Jennison Associates LLC Lowers Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Jennison Associates LLC lessened its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 26.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 303,521 shares of the company’s stock after selling 106,536 shares during the period. Jennison Associates LLC owned 1.06% of Krystal Biotech worth $47,550,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in KRYS. Wilmington Savings Fund Society FSB bought a new stake in shares of Krystal Biotech during the third quarter valued at approximately $40,000. Values First Advisors Inc. purchased a new position in Krystal Biotech during the 3rd quarter worth $53,000. GAMMA Investing LLC raised its position in Krystal Biotech by 184.8% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock valued at $78,000 after purchasing an additional 279 shares in the last quarter. Huntington National Bank lifted its holdings in shares of Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after buying an additional 283 shares during the period. Finally, Blue Trust Inc. grew its position in shares of Krystal Biotech by 242.4% during the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after buying an additional 412 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $161.30 on Wednesday. The firm’s 50 day simple moving average is $164.94 and its 200-day simple moving average is $178.99. Krystal Biotech, Inc. has a 12 month low of $107.50 and a 12 month high of $219.34. The stock has a market capitalization of $4.64 billion, a price-to-earnings ratio of 91.13 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. During the same quarter in the previous year, the company earned ($0.67) earnings per share. The firm’s revenue for the quarter was up 879.9% on a year-over-year basis. Analysts anticipate that Krystal Biotech, Inc. will post 3.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

KRYS has been the subject of a number of research reports. Chardan Capital reaffirmed a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, Citigroup lifted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $206.67.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).